Vitamin D, a steroid prohormone best known for its role in bone health and metabolism, also plays an important role in reproductive immune regulatory functions in both the nonpregnant and pregnant states. [@JR190021-1] [@JR190021-2] Vitamin D deficiency, defined as a 25(OH)D concentration \< 12 ng/mL by the Institute of Medicine, on the basis of increased rickets or osteomalacia risk in children and adults, [@OR190021-3] is estimated to affect 83% of pregnant women in the first trimester and 47% of pregnant women in the third trimester. [@JR190021-4] [@JR190021-5] Vitamin D enhances innate immune function via toll-like receptor activation, inducing increased secretion of endogenous microbicides such as cathelicidin [@JR190021-1] in response to microbial pathogens within the female genital tract. Vitamin D deficiency also puts pregnant women at higher risk for preterm birth, [@JR190021-6] [@JR190021-7] preeclampsia, [@JR190021-8] gestational diabetes, as well as delivery of a small-for-gestational age neonate. [@JR190021-8] [@JR190021-9] While optimal supplementation dosing has not been firmly established, prior trials suggest optimal conversion to the active form of vitamin D occurs at serum concentrations ≥ 40 ng/mL in pregnancy. [@JR190021-10] [@JR190021-11] Wagner et al [@JR190021-7] suggested that in pregnancy, optimal conversion of 25(OH)D to 1,25(OH) ~2~ D, as well as reduced preterm birth rates among women, was most significant when 25(OH)D concentrations ≥ 40 ng/mL were achieved. Using this cutoff, \>70% of pregnant women would be considered vitamin D deficient. [@JR190021-12] Thus, vitamin D deficiency may represent an under-appreciated public health problem with a low-cost solution and positive impact on pregnancy outcomes.

Bacterial vaginosis (BV) affects almost 30% of reproductive age women in the United States, [@JR190021-13] resulting from an overgrowth of anaerobic vaginal microbes and loss of lactobacilli. In pregnancy, BV is associated with an increased risk of preterm birth, [@JR190021-14] [@JR190021-15] [@JR190021-16] postpartum endometritis, [@JR190021-17] and acquisition of sexually transmitted infections. [@JR190021-18] [@JR190021-19] [@JR190021-20] Most observational studies have identified a higher prevalence of BV among women who are vitamin D insufficient or deficient [@JR190021-21] [@JR190021-22] [@JR190021-23] ; with one identifying a null association. [@JR190021-24] In a vitamin D supplementation randomized controlled trial (RCT), Turner et al did not demonstrate a reduction in BV recurrence in 118 nonpregnant women. [@JR190021-25] To the best of our knowledge, there are no previously published RCTs of vitamin D supplementation investigating an impact on BV incidence in pregnancy. Since improved pregnancy outcomes may not be significant until a serum 25(OH)D concentration of at least 40 ng/mL is achieved, it is still unclear if vitamin D supplementation may result in a reduction of BV in pregnancy. Although there is insufficient evidence that screening and treatment of asymptomatic BV alone during pregnancy reduce the incidence of preterm birth, prevention of BV by way of correcting vitamin D deficiency may be more beneficial and has not been studied to date.

Our primary objective was to investigate the association between BV and vitamin D concentration in a nested cohort from an RCT of pregnant women. Our secondary objective was to evaluate if vitamin D supplementation decreased BV incidence in pregnancy. We hypothesized that women with vitamin D deficiency would be more likely to experience BV during pregnancy and women supplemented to a 25(OH)D concentration ≥ 40 ng/mL would be less likely to experience a new BV episode in pregnancy.

Methods
=======

This study was approved by the Institutional Review Board of the Medical University of South Carolina (Protocol \#20570) and all subjects provided written informed consent. This was a preplanned analysis within a larger RCT of 450 pregnant women, 18 to 45 years old with singleton pregnancies, enrolled between 8 and 14 weeks of gestation and followed until delivery between 2013 and 2015 (ClinicalTrials.gov, trial \#NCT01932788) ( [Fig. 1](#FI190021-1){ref-type="fig"} ). Mothers were randomized to receive the standard daily prenatal vitamin (containing 400 IU vitamin D ~3~ ) ± 4,000 IU vitamin D ~3~ daily. Subjects were followed up monthly during pregnancy up to a total of nine study visits.

Subjects were excluded from the parent study if they had a preexisting calcium disorder, uncontrolled thyroid or parathyroid disease, requirement for chronic diuretic or cardiac medication therapy including calcium-channel blockers, sickle cell disease, sarcoidosis, or inflammatory bowel disease. A subgroup of ∼100 subjects with known diabetes, hypertension, or body mass index (BMI) \> 49 kg/m ^2^ did participate but were excluded from analysis in the present study. A sample size of 240 subjects, 120 in each arm, was calculated to be sufficient to detect a clinically important difference of 0.3 between groups in achieving a total circulating 25(OH)D concentration of at least 40 ng/mL assuming a standard deviation of 10 using a two-tailed *t* -test of difference between means with 80% power and a 5% level of significance. The total sample size was adjusted to 264 (132 per group) giving consideration to a dropout rate of 10%. A stratified block randomization was used to attain equal group numbers and balanced numbers by racial/ethnic group. Adherence to treatment was assessed by monthly pill count and women with an adherence rate of \< 60% predicted pill intake for 2 consecutive months exited the study ( *n*  = 60: 7 white/Caucasian; 18 Hispanic; and 35 black/African American \[AA\] women). The parent study was not powered to detect a difference in BV as a clinical outcome.

Subjects were included in this current analysis if they had at least one vaginal sample measured for BV ( *n*  = 257). In the present study, subjects ( *n*  = 13 total) were excluded from the BV analysis if spontaneous abortion (\< 20 weeks\' gestation) ( *n*  = 10) or intrauterine fetal demise (all \< 30 weeks) ( *n*  = 3) was diagnosed during the pregnancy. From the original cohort, 133 women from the 4,400 IU group and 112 from the control group were included in the current analysis.

Target vitamin D was defined as a plasma 25(OH)D concentration of ≥ 40 ng/mL based on prior pharmacokinetics studies. [@JR190021-26] 25(OH)D concentrations were measured monthly, corresponding to the timing of obtained vaginal swabs at study visits in the first, second, and third trimesters prior to delivery. Initial visit, visit 4, and visit 7 samples were obtained between 8 and 15, 22 and 28, and 31 and 41 weeks of gestation, respectively. If the subject delivered prior to 36 weeks, their last known 25(OH)D concentration and vaginal swab information were used. For the purposes of our analysis, vitamin D insufficiency was defined as \< 40 ng/mL [@JR190021-26] and vitamin D deficiency was \< 20 ng/mL [@OR190021-3] ). Race and ethnicity were self-reported.

Bacterial Vaginosis Diagnosis
-----------------------------

Vaginal swabs were collected on all participants each trimester to correspond to the timing of the 25(OH)D measurements prior to delivery and analyzed by Gram stain and Nugent score calculation. [@JR190021-27] According to the Nugent method, women with a Nugent score of 7 to 10 were considered to have BV. The Nugent score is a Gram stain scoring system calculated by assessment of the presence of gram-positive rods, small gram-variable rods, and curved gram-variable rods per high power field. A Nugent score can range from 0 to 10; 0 to 3 is considered normal vaginal flora, 4 to 6 is considered intermediate flora, and 7 or greater is consistent with BV. Vaginal swabs were collected for 216, 222, and 209 subjects at visits 1, 4, and 7, respectively. Development of BV was defined as having a Nugent score \< 7 at visit 1 and ≥ 7 at visit 4 or 7.

Measurement of 25-hydroxyvitamin D
----------------------------------

Whole blood samples were obtained, placed in EDTA-treated tubes and centrifuged for plasma separation. Plasma was then stored at −80°C until measurement for total circulating 25(OH)D concentrations, measured by radioimmunoassay as per the manufacturer\'s protocol (DiaSorin, Stillwater, MN). The standard deviation for 25(OH)D concentration was 7 to 10 ng/mL. The laboratory participated in Vitamin D External Quality Assessment Scheme throughout the study period to ensure the analytical reliability of the 25(OH)D assay using National Institute of Standards and Technology standards. The inter- and intra-assay coefficients of variation were \< 10%.

Timing of Vitamin D Supplementation
-----------------------------------

Subjects from the parent study were randomized to 4,000 IU cholecalciferol versus placebo following enrollment. Thus, baseline measurements at visit 1 were obtained before randomization.

Statistical Analysis
--------------------

Statistical analyses were performed using SAS 9.4 software (Cary, NC). Binomial data were compared using chi-square and Fischer\'s exact tests depending on the sample size. The Shapiro--Wilk\'s analysis was used to evaluate continuous variables for normal distribution. Normally distributed continuous variables were described as means with standard deviation and nonnormally distributed continuous variables were described as medians with a corresponding interquartile range. Continuous variables were analyzed using Student\'s *t* -test and Wilcoxon\'s rank-sum test; categorical variables were analyzed by chi-square and Fisher\'s exact tests. Mixed logistic regression was created using a forward iterative process to account for repeated measures over time using SAS 9.4 PROC GLIMMIX procedure (Cary, NC) with the primary outcome variable chosen as BV development. BV prevalence over time was modeled by linear mixed effects. Vitamin D concentration (continuous), gestational age, age (continuous), race/ethnicity, and prepregnancy BMI (continuous) were chosen for fixed effects, while subject identification was used as the random effect. Variables included in the model were chosen by significance in univariate analysis at the *p*  \< 0.2 threshold. Pregnancy outcomes of interest in the regression model included gestational hypertension, preeclampsia, hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome, chorioamnionitis, and preterm birth.

Results
=======

Among all study subjects, 245 women with at least one vaginal smear available for Gram staining were included in the current analysis. Included subjects having a median age of 29 years were predominantly non-Hispanic white race and had a mean prepregnancy BMI of 25.9 kg/m ^2^ . A majority were privately insured and had finished college ( [Table 1](#TB190021-1){ref-type="table"} ). Chlamydia was the most common sexually transmitted infection diagnosed in pregnancy (5%), followed by herpes simplex virus. At initial visit (8--13 weeks), the mean 25(OH)D concentration was 26.2 ng/mL (±9.5 ng/mL), which increased to a mean concentration of 42.4 ng/mL (±18.6 ng/mL) by delivery. Almost 5% of participants experienced preterm delivery (\< 37 weeks\' gestation). The second most common complication of pregnancy was preeclampsia (4.1%) ( [Fig. 1](#FI190021-1){ref-type="fig"} ).

###### Demographics for study participants with and without BV at baseline

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                          All subjects with BV screening ( *n*  = 245)   BV present at baseline ( *n*  = 52)   No BV at baseline ( *n*  = 167)   *p* -Value
  --------------------------------------------------------------------------------------- ---------------------------------------------- ------------------------------------- --------------------------------- ------------
  Age (y) [a](#FN190021-2){ref-type="table-fn"}                                           29 (±4.76)                                     25 (±5.2)                             29 (±4.5)                         0.055

  BMI [a](#FN190021-2){ref-type="table-fn"}                                               25.9 (±5.76)                                   26.7 (±6.5)                           25.9 (±5.7)                       0.76

  Gravidity [b](#FN190021-3){ref-type="table-fn"}                                         2 (1--3)                                       2 (1.5--4)                            2 (1--3)                          0.57

  Parity [b](#FN190021-3){ref-type="table-fn"}                                            1 (0--2)                                       1 (0--2)                              1 (0--2)                          0.42

  Race/ethnicity                                                                                                                                                                                                 

   Caucasian                                                                              100 (40.8%)                                    8 (15.4%)                             82 (49.1%)                        \< 0.001

   African American                                                                       68 (27.8%)                                     29 (55.8%)                            37 (22.2%)                        

   Hispanic                                                                               77 (31.4%)                                     15 (28.9%)                            48 (28.7%)                        

  Insurance type                                                                                                                                                                                                 

   Self-pay/none                                                                          62 (25.3%)                                     8/52 (15.4%)                          41/167 (24.6%)                    \< 0.001

   Public insurance                                                                       67 (27.3%)                                     29/52 (55.8%)                         37/167 (22.2%)                    

   Private insurance                                                                      116 (47.3%)                                    15/52 (28.9%)                         89/167 (53.3%)                    

  Highest education level                                                                                                                                                                                        

   More than high school                                                                  Finished high school---116 (47.3%)\            24/49 (49%)                           120/171 (70.2%)                   0.003
                                                                                          Finished college---59 (24.1%)                                                                                          

   Less than high school                                                                  31 (12.6%)                                     25/49 (51%)                           51/171 (29.8%)                    

  Sexually transmitted infection in pregnancy                                                                                                                                                                    

   Gonorrhea                                                                              2 (0.9%)                                       1/52 (1.9%)                           1/167 (0.6%)                      0.42

   Chlamydia                                                                              11 (5%)                                        5/52 (9.6%)                           6/167 (3.5%)                      0.14

   Trichomonas                                                                            9 (4.1%)                                       2/52 (3.85%)                          7/167 (4.19%)                     1.0

   Syphilis                                                                               0                                              0                                     0                                 

   Herpes simplex virus                                                                   10 (4.6%)                                      0                                     10/166 (6.02%)                    0.12

   HIV (prevalent)                                                                        0                                              0                                     0                                 

  Mean 25(OH)D concentration in pregnancy (ng/mL) [a](#FN190021-2){ref-type="table-fn"}                                                                                                                          

   8--15 wk (visit 1)                                                                     26.2 (±9.5)                                    23.7 (±8.3)                           26.3 (±9.8)                       0.05

   21--28 wk (visit 4)                                                                    38.7 (±14.7)                                   34.9 (±15.6)                          39.8 (±14.2)                      0.03

   31--41 wk (visit 7)                                                                    42.4 (±18.6)                                   36.7 (±19.8)                          44.8 (±17.3)                      0.056

  Pregnancy outcome of interest                                                                                                                                                                                  

   Gestational hypertension                                                               8/245 (3.3%)                                   3/52 (5.8%)                           5/167 (2.99%)                     0.40

   Preeclampsia                                                                           10/245 (4.1%)                                  3/52 (5.8%)                           5/167 (3.0%)                      0.40

   Chorioamnionitis                                                                       7/245 (2.9%)                                   2/52 (3.9%)                           5/167 (3.0%)                      0.67

   Preterm birth (\< 37 wk)                                                               12/245 (4.9%)                                  3/52 (5.8%)                           6/167 (3.6%)                      0.45

  Vitamin D treatment group allocation                                                                                                                                                                           

   Treatment group (vitamin D supplement = 4,000 IU daily)                                133/245 (54.3%)                                26/52 (50%)                           92/167 (55.1%)                    0.52
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BMI, body mass index; BV, bacterial vaginosis; HIV, human immunodeficiency virus; 25(OH)D, 25-hydroxyvitamin D.

Continuous variables are reported as mean values with standard deviation. Univariate analysis performed by Wilcoxon\'s rank-sum test.

Median with interquartile range. Categorical variables were analyzed by chi-square test and Fisher\'s exact test.

![CONSORT diagram for Kellogg Study and bacterial vaginosis cohort. Note: Subcohort group not used in analysis.](10-1055-s-0039-1693163-i190021-1){#FI190021-1}

Mean 25(OH)D Concentration by Randomization Group
-------------------------------------------------

Study participants in treatment (4,000 + 400 IU in prenatal vitamin) versus control (400 IU in prenatal vitamin) arm had statistically significantly different 25(OH)D concentrations at 21 to 28 weeks ( *p*  \< 0.0001) and 31 to 41 weeks ( *p*  \< 0.0001) ( [Table 1](#TB190021-1){ref-type="table"} ). [Fig. 2](#FI190021-2){ref-type="fig"} shows mean 25(OH)D concentrations throughout the study period by randomization group.

![Mean 25-hydroxyvitamin D concentration (ng/mL) by randomization group.](10-1055-s-0039-1693163-i190021-2){#FI190021-2}

Significant differences in 25(OH)D concentrations were also apparent throughout the study period when stratified by race, randomization group, and prepregnancy BMI. Among AA women, 61.8% had 25(OH)D concentrations \< 40 ng/mL at visit 7 ( [Table 2](#TB190021-2){ref-type="table"} ). AA women were significantly more likely to have 25(OH)D concentrations \< 20 ng/mL at all three time points ( *p*  \< 0.0001, *p*  = 0.0004, and *p*  = 0.0007, respectively). 25(OH)D concentrations were significantly different at visits 4 ( *p*  \< 0.0001) and 7 ( *p*  \< 0.0001) by randomization group among study participants. Women with a prepregnancy BMI ≥ 30 kg/m ^2^ were significantly more likely to have a 25(OH)D concentration \< 40 ng/mL.

###### Percentage of study participants with 25(OH)D concentration more than or Less than 40 or 20 ng/mL stratified by race/ethnicity [a](#FN190021-5){ref-type="table-fn"}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Race                 25(OH)D (ng/mL)\   25(OH)D (ng/mL)\   25(OH)D (ng/mL)\                                                                                                
                       8--13 wk           22--24 wk          25--36 wk                                                                                                       
  -------------------- ------------------ ------------------ -------------------- ----------------- ---------------- -------------------- ----------------- ---------------- --------------------
                       **\< 40 ng/mL**    **≥ 40 ng/mL**     ***p*** **-Value**   **\< 40 ng/mL**   **≥ 40 ng/mL**   ***p*** **-Value**   **\< 40 ng/mL**   **≥ 40 ng/mL**   ***p*** **-Value**

  Non-Hispanic white   82 (82%)           18 (18%)           0.0002               39 (39%)          61 (61%)         0.002                32 (32%)          68 (68%)         0.0006

  Non-Hispanic black   66 (97%)           2 (3%)             43 (63.2%)           25 (36.8%)        42 (61.8%)       26 (38.24%)                                             

  Hispanic             75 (97.4%)         2 (2.6%)           47 (61%)             30 (39%)          37 (48%)         40 (52%)                                                

                       **\< 20 ng/mL**    **≥ 20 ng/mL**     ***p*** **-Value**   **\< 20 ng/mL**   **≥ 20 ng/mL**   ***p*** **-Value**   **\< 20 ng/mL**   **≥ 20 ng/mL**   ***p*** **-Value**

  Non-Hispanic white   11 (11%)           89 (89%)           \<0.0001             1 (1%)            99 (99%)         0.0004               0                 \(1\) 100%       0.0007

  Non-Hispanic black   31 (45.6%)         37 (54.4%)         12 (17.7%)           56 (82.4%)        10 (14.7%)       58 (85.3%)                                              

  Hispanic             18 (23.4%)         59 (76.6%)         6 (7.8%)             71 (92.2%)        9 (11.7%)        68 (88.3%)                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: 25(OH)D, 25-hydroxyvitamin D.

Calculated from chi-square and Fisher\'s exact tests.

Baseline BV
-----------

Based on a Nugent score of 7 to 10, BV was diagnosed in 52 women at initial visit (21.2%). Compared with women who did not have BV at baseline, these subjects were not significantly younger (mean age 25 vs. 29 years, *p*  = 0.055), but more likely to be AA (55.8 vs. 22.2%, *p*  \< 0.001), covered under public insurance (55.8 vs. 22.2%, *p*  \< 0.001), and significantly less likely to have more than a high school education ( [Table 1](#TB190021-1){ref-type="table"} ; *p*  = 0.003). Of note, 70.2% of AA women were covered under public insurance. Women with BV at baseline also had significantly lower mean 25(OH)D concentrations at 8 to 15 weeks (visit 1) and 21 to 28 weeks (visit 4) (visit 1, *p*  = 0.05; visit 4, *p*  = 0.03). There were no significant differences in pregnancy outcomes of interest among women with and without BV at baseline. [Fig. 3](#FI190021-3){ref-type="fig"} demonstrates BV prevalence by randomization group throughout pregnancy.

![Bacterial vaginosis (BV) prevalence by randomization group.](10-1055-s-0039-1693163-i190021-3){#FI190021-3}

BV Development in Pregnancy
---------------------------

Sixteen women developed BV during pregnancy and were significantly younger than those who did not (26.5 vs. 29 years; *p*  = 0.02). There were no other differences noted in terms of race/ethnicity, prepregnancy BMI, insurance type, education level, or incidence of sexually transmitted infections ( [Table 3](#TB190021-3){ref-type="table"} ). There were also no significant differences in mean 25(OH)D concentrations throughout pregnancy or among pregnancy outcomes of interest between women who did and did not develop BV during pregnancy. In univariate analysis, only prepregnancy BMI category was significantly associated (unadjusted odds ratio: 0.72, 95% confidence interval: 1.01--4.2, *p*  = 0.046) with BV development; however, this variable was no longer significant following adjustment for race, age, treatment group, and 25(OH)D concentrations at each time point by multivariate logistic regression. Per cent change in vitamin D concentrations between visits 1 and 4, 4 and 7, and 1 and 7 were calculated and did not significantly correlate with BV prevalence.

###### Demographics for study participants who did and did not develop BV during pregnancy [a](#FN190021-7){ref-type="table-fn"}

                                                       BV developed during pregnancy ( *n*  = 16) [a](#FN190021-7){ref-type="table-fn"}   No BV developed during pregnancy ( *n*  = 216)   *p* -Value
  ---------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------ ------------
  Age (y) [b](#FN190021-8){ref-type="table-fn"}        26.5 (±5.1)                                                                        29 (±4.7)                                        0.022
  BMI [b](#FN190021-8){ref-type="table-fn"}            26.1 (±7.5)                                                                        26.0 (±5.7)                                      0.13
  Gravidity [c](#FN190021-9){ref-type="table-fn"}      3 (2--4)                                                                           2 (1--3)                                         0.43
  Parity [c](#FN190021-9){ref-type="table-fn"}         1 (1--2)                                                                           1 (0--2)                                         0.19
  Race/ethnicity                                                                                                                                                                           
   Caucasian                                           4 (25%)                                                                            90 (41.7%)                                       0.42
   African American                                    6 (37.5%)                                                                          62 (28.7%)                                       
   Hispanic                                            6 (37.5%)                                                                          64 (29.6%)                                       
  Insurance type                                                                                                                                                                           
   Self-pay/none                                       4 (25%)                                                                            51 (23.6%)                                       0.32
   Public insurance                                    7 (43.8%)                                                                          60 (27.8%)                                       
   Private insurance                                   5 (31.3%)                                                                          105 (48.6%)                                      
  Highest education level                                                                                                                                                                  
   More than high school                               8/16 (50%)                                                                         142/216 (65.7%)                                  0.21
   Less than high school                               8/16 (50%)                                                                         74/216 (34.2%)                                   
  Sexually transmitted infections in pregnancy                                                                                                                                             
   Gonorrhea                                           1/16 (6.3%)                                                                        1/216 (0.46%)                                    0.14
   Chlamydia                                           2/16 (12.5%)                                                                       9/216 (4.2%)                                     0.17
   Trichomonas                                         1/16 (6.3%)                                                                        8/216 (3.7%)                                     0.48
   Syphilis                                            0                                                                                  0                                                0
   Herpes simplex virus                                1/16 (6.3%)                                                                        9/215 (4.19%)                                    0.52
   HIV (prevalent)                                     0                                                                                  0                                                0
  Mean 25(OH)D concentration in pregnancy (ng/mL)                                                                                                                                          
   8--15 wk (visit 1)                                  22.05 (±8.4)                                                                       26.3 (±9.6)                                      0.72
   21--28 wk (visit 4)                                 36.5 (±12.8)                                                                       38.7 (±15.1)                                     0.61
   31--41 wk (visit 7)                                 47.6 (±15.9)                                                                       42.2 (±19.0)                                     0.98
  Pregnancy outcome of interest                                                                                                                                                            
   Gestational HTN                                     0                                                                                  8/216 (3.7%)                                     1.0
   Preeclampsia                                        0                                                                                  9/216 (4.2%)                                     1.0
   Chorioamnionitis                                    1/16 (6.3%)                                                                        6/216 (2.8%)                                     0.4
   Preterm birth                                       1/16 (6.3%)                                                                        9/216 (4.2%)                                     0.52
  Vitamin D treatment group allocation                                                                                                                                                     
   Treatment group (vitamin D supplement = 4,000 IU)   10/16 (62.5%)                                                                      114/216 (52.8%)                                  0.45

Abbreviations: BV, bacterial vaginosis; HIV, human immunodeficiency virus; HTN, hypertension; 25(OH)D, 25-hydroxyvitamin D.

Women with BV at baseline were excluded from this analysis.

Continuous variables are reported as mean values with standard deviation. Univariate analysis performed by Wilcoxon\'s rank-sum test.

Median with interquartile range. Categorical variables were analyzed by chi-square test and Fisher\'s exact test.

Vitamin D Concentration and BV Prevalence
-----------------------------------------

Overall, the relationship between 25(OH)D concentration and BV was not strong or statistically significant. The unadjusted baseline 25(OH)D was significantly associated with BV at visit 1 ( *p*  = 0.01) but not with BV development in pregnancy ( *p*  = 0.14). Following adjustment for age, race/ethnicity, gestational age, and prepregnancy BMI, this relationship between baseline 25(OH)D and BV was no longer significant. While [Fig. 3](#FI190021-3){ref-type="fig"} demonstrates an apparent increase in BV prevalence by 31 to 41 weeks in the treatment group (4,400 IU supplement) compared with controls, this trend was not statistically different ( *p*  = 0.22) and was similar across all racial groups. [Fig. 4](#FI190021-4){ref-type="fig"} demonstrates this relationship with an unadjusted area under the curve = 0.611 by receiver-operating characteristic curve. BV was significantly more prevalent among AA compared with Caucasian women at visits 4 ( *p*  = 0.01) and 7 ( *p*  = 0.007). In a linear mixed-effects model, age ( *p*  = 0.02) and race/ethnicity ( *p*  = 0.0002) were significant predictors for BV. Vitamin D concentration ( *p*  = 0.81), gestational age ( *p*  = 0.06), and prepregnancy BMI ( *p*  = 0.87) were not significant predictors. The influence of race/ethnicity was found to overpower that of vitamin D concentration with different iterations of the model. When modeling BV prevalence over time just among AA women, it, however, still showed no significant effect of vitamin D concentration either as a continuous or categorical variable (at 40 or 20 ng/mL levels).

![Unadjusted ROC curve for 25(OH)D (VD) concentration and BV. AUC, area under the curve; BV, bacterial vaginosis; ROC, receiver-operating characteristic; VD, vitamin D; 25(OH)D, 25-hydroxyvitamin D.](10-1055-s-0039-1693163-i190021-4){#FI190021-4}

Discussion
==========

In this nested cohort from the Kellogg Pregnancy Study RCT, baseline vitamin D deficiency and vitamin D supplementation did not appear to have a significant impact on incidence or prevalence of BV during pregnancy, after accounting for race/ethnicity, age, and prepregnancy BMI. Consistent with prior reports in the literature, race was an independent, significant predictor for BV. It is reasonable to compare our results with previous studies because there does not appear to be any evidence that BV is more common in pregnancy. Our results are also consistent with the previously published RCT investigating vitamin D supplementation to reduce BV recurrence in nonpregnant women, which showed no significant difference in BV recurrence based on randomized treatment group. Subjects in our study had higher mean plasma 25(OH)D concentrations at trial completion, compared with previous studies. [@JR190021-25] [@JR190021-28] While a dose-dependent effect of vitamin D appears to impact other pregnancy outcomes, it did not appear to significantly impact BV diagnosis in pregnancy.

BV is known to cause a localized inflammatory response in the vagina. [@JR190021-13] [@JR190021-29] [@JR190021-30] It is also associated with altered cervicovaginal inflammatory cytokines [@JR190021-13] [@JR190021-31] and absent antimicrobial peptides. [@JR190021-32] Thus, vitamin D plays a plausible role within the female genital tract by altering the innate immune response to pathogens such as BV. Vitamin D receptors are present on many cells of the female genital tract, which regulate expression of cathelicidin antimicrobial peptides [@JR190021-2] [@JR190021-33] which, in turn, may protect the female genital tract. In support of this hypothesis, vitamin D receptor knockout mice have significantly decreased intestinal lactobacilli concentrations. In the human vagina, decreased lactobacilli concentration is associated with vaginal dysbiosis. [@JR190021-33] While not currently known, there may still be a dose-dependent effect of vitamin D on the female genital tract, which may be further affected by race and pregnancy. Additional factors not studied in our RCT may mitigate this effect.

Strengths of this study include a relatively large sample size and randomized study design, as well as consistent Nugent score reading by one investigator (A.M.P.). The sample size may not have provided enough power to detect racial differences in BV by 25(OH)D concentration, however. More subtle differences between groups may also not have been detectable by Gram stain or Nugent score assignment. Additional limitations include the possible confounding biological effects of AA race and vitamin D supplementation; however, even after isolating the race variable, no significant effect of vitamin D supplementation on BV prevalence was observed. Clearly, additional studies would be needed to further delineate the role of vitamin D and the impact of supplementation on the female genital tract and its microbiome, and particularly during pregnancy. A matched case--control design could further clarify racial differences and effects of vitamin D supplementation on the incidence of BV.

Conclusion
==========

Vitamin D supplementation did not appear to have a significant impact on incidence or prevalence of BV during pregnancy, even after accounting for race, age, and treatment group assignment.
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